Divalproex Sodium Tablet, Extended Release
Product Images NDC 70518-3183

8 FDA label images from Remedyrepack Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 70518-3183). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1 (1638e85a 579b 4286 8f77 49f9e6c88488 01)

Image 1 (1638e85a 579b 4286 8f77 49f9e6c88488 01)
Chemical structure diagram of divalproex sodium showing its molecular composition and arrangement with sodium ion indicated.*
FDA Label Image

Image 2 (1638e85a 579b 4286 8f77 49f9e6c88488 02)

Image 2 (1638e85a 579b 4286 8f77 49f9e6c88488 02)
A cumulative percentage plot showing the percent reduction in CPS rate among patients treated with Divalproex Sodium Delayed-Release compared to placebo. The x-axis represents the percentage of patients, and the y-axis shows the percent reduction in CPS rate, with higher values indicating improvement and lower values indicating worsening. The solid line represents Divalproex Sodium, and the dashed line represents placebo.*
FDA Label Image

Image 3 (1638e85a 579b 4286 8f77 49f9e6c88488 03)

Image 3 (1638e85a 579b 4286 8f77 49f9e6c88488 03)
A graph showing the percentage reduction in Clinical Pain Score (CPS) rate versus the percentage of patients treated with high and low doses of Divalproex Sodium Delayed Release. The y-axis indicates improvement or worsening in CPS, while the x-axis shows the proportion of patients. Two curves compare high dose and low dose effects on CPS reduction.*
FDA Label Image

Image 4 (1638e85a 579b 4286 8f77 49f9e6c88488 04)

Image 4 (1638e85a 579b 4286 8f77 49f9e6c88488 04)
A bar chart comparing numerical values between placebo and Divalproex Sodium Extended-Release Tablets. The chart shows a value of 0.6 for placebo and 1.2 for Divalproex Sodium, with an asterisk indicating statistical significance (p=0.006).*
FDA Label Image

Image (9f0c730e 9756 4a9a 9277 B4ef5ca07604 201 1)

Image (9f0c730e 9756 4a9a 9277 B4ef5ca07604 201 1)
Divalproex sodium 250 mg extended release oral tablets packaging label. The image shows a white rectangular blister card containing 14 tablets arranged in two columns. The labeler is Remedyrepack Inc.*
FDA Label Image

Mm1 (Divalproex Sodium 250mg 70518 3183 00)

Mm1 (Divalproex Sodium 250mg 70518 3183 00)
Label for Divalproex Sodium Tablet Extended-Release 250 mg, oral tablet form. The label shows a quantity of 30 tablets packaged by RemedyRepack Inc. It includes storage instructions and a QR code. The manufacturer is Lupin Pharma, Baltimore, MD. The NDC number is 70518-3183-00.*
FDA Label Image

Mm2 (Divalproex Sodium 250mg 70518 3183 01)

Mm2 (Divalproex Sodium 250mg 70518 3183 01)
Divalproex Sodium Tablet Extended-Release 250 mg oral tablets, packaged 100 per box. The label shows the product name, strength, extended-release form, and quantity. Manufactured by Lupin Ltd, India, and repackaged by RemedyRepack Inc., Indiana, PA, with NDC 70518-3183-01. Storage instructions and usual dosage reference are also visible.*
FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
Divalproex Sodium 250 mg extended-release tablets, 30 count, repackaged by RemedyRepack Inc. The label includes dosage form and quantity, manufacturer Lupin Pharma details, storage instructions, and a QR code. It is marked RX only and advises to see the package insert for directions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.